Merck & Co., Inc. KYMR — KYMERA THERAPEUTICS INC

Ownership history in Merck & Co., Inc.  ·  7 quarters on record

AI Ownership Summary

Merck & Co., Inc. reported KYMERA THERAPEUTICS INC (KYMR) in 7 quarterly 13F filings from 2024 Q4 through 2026 Q2. Peak portfolio weight reached 21.75% in 2025 Q4. The latest visible filing shows KYMR at 16.82% of the fund.

This page tracks quarterly shares, estimated market value, portfolio weight, filing dates, and disclosure-aligned stock prices directly from SEC EDGAR 13F filings.

What this KYMR ownership page tells you

This page is designed to answer the real investor question behind a 13F filing: how meaningful was Merck & Co., Inc.'s position in KYMERA THERAPEUTICS INC, and how did that conviction change over time? You can read the holding window, peak weight, latest reported size, disclosure timing, and quarter-by-quarter changes without piecing the story together from raw SEC rows.

Freshest filing
Latest Reported Filing
2026 Q2

KYMR was reported at 16.82% of portfolio in the most recent visible filing.

High-water mark
Peak Conviction
21.75% in 2025 Q4

Peak weight helps separate a token disclosure from a real conviction holding the fund genuinely cared about.

Time in book
Holding Window
2024 Q4 to 2026 Q2

Longer holding windows often tell a very different story from short-lived tactical trades or one-quarter experiments.

Decision context
Why It Matters
Position size beats headlines

Knowing that a fund owned a stock is useful. Knowing whether it was a 0.20% placeholder or a true high-conviction position is where the signal actually starts.

KYMR stock page Merck & Co., Inc. fund profile Merck & Co., Inc. full holdings
How Merck & Co., Inc. held KYMR — position size vs. price
% of Fund (quarterly)    KYMR price (quarter-end, indexed to 100)    SPY (indexed to 100)    QQQ (indexed to 100)
📋 Quarterly Holdings History 7 quarters  ▾
Quarter Action Sold % After 3M Timing Shares Change Chg % % of Fund Mkt Value Filed Price (Filed)
2026 Q2 UNCHANGED — — — 772,165 — 0% 16.82% $88.5M 2026-08-07 $107.52
2026 Q1 UNCHANGED — — — 772,165 — 0% 18.40% $64.3M 2026-05-13 $85.59
2025 Q4 UNCHANGED — — — 772,165 — 0% 21.75% $60.1M 2026-02-17 $84.84
2025 Q3 UNCHANGED — — — 772,165 — 0% 19.17% $43.7M 2025-11-12 $63.53
2025 Q2 UNCHANGED — — — 772,165 — 0% 15.63% $33.7M 2025-08-13 $40.73
2025 Q1 UNCHANGED — — — 772,165 — 0% 12.86% $21.1M 2025-05-14 $29.75
2024 Q4 INITIATED — — — 772,165 — — 12.04% $31.1M 2025-02-14 $36.88

🏢 Other funds also holding KYMR

As of 2026 Q2 — sorted by position size

AJU IB Investment Co., Ltd. 3Y 5.36% Eagle Health Investments LP 3Y 3.16% MOODY ALDRICH PARTNERS LLC 3Y 7Y 0.62% AlphaCentric Advisors LLC 3Y 0.52% Persistent Asset Partners Ltd 0.31% HARBOR CAPITAL ADVISORS, INC. 3Y 0.28% TimesSquare Capital Management, LLC 3Y 7Y 0.27% Pier Capital, LLC 3Y 7Y 0.26% PSP Research LLC 0.24% PEREGRINE CAPITAL MANAGEMENT LLC 3Y 7Y 0.17%

FAQ About Merck & Co., Inc. and KYMR

These are the practical questions this page is built to answer before you even open the full history table.

How long has Merck & Co., Inc. reported owning KYMR?

Merck & Co., Inc. reported KYMR across 7 quarterly 13F filings, from 2024 Q4 through 2026 Q2.

What was the largest reported KYMR position in Merck & Co., Inc.'s portfolio?

The largest reported portfolio weight for KYMR was 21.75% in 2025 Q4.

What is the latest reported KYMR position on this page?

The most recent filing on this page is 2026 Q2, when Merck & Co., Inc. reported 772,165 shares, equal to 16.82% of portfolio, with an estimated market value of $88.5M.

What does the chart on this KYMR ownership page compare?

The chart compares Merck & Co., Inc.'s quarterly KYMR portfolio weight with the stock's indexed share price, so you can see whether the fund was building, trimming, or holding the position as price moved.

← Back to Merck & Co., Inc. Holdings